Table 4.

Mean (±Standard Deviation) Revusiran-Related Clinical Chemistry Changes in 6- and 39-Week Toxicity Studies in Monkeys

	6-Week toxicity study
	Males				Females
	Dose (mg/kg)
	0	30	100	300	0	30	100	300
	No. animals/group
	5	5	5	5	5	5	5	5
ALP (U/L)	Pre-study (week 2)
	582 ± 182.2	517 ± 151.0	680 ± 118.8	702 ± 260.7	442 ± 60.6	428 ± 82.9	489 ± 146.5	513 ± 76.0
	Day 6
	447 ± 122.0	582 ± 240.7	1,182 ± 343.4*	1,536 ± 559.6***	373 ± 64.6	485 ± 114.6	891 ± 302.6***	1,284 ± 337.3***
	Day 37a
	551 ± 140.3	623 ± 209.6	818 ± 186.0	1,076 ± 596.2	433 ± 80.9	522 ± 104.6	819 ± 278.5*	852 ± 194.5**

	39-Week toxicity study
	Males				Females
	Dose (mg/kg)
	0	15	75	200	0	15	75	200
	No. animals/group
	6	6	6	6	6	6	6	6
ALP (U/L)	Pre-study (week 2)
	403 ± 103.2	340 ± 46.3	309 ± 84.6	293 ± 57.6	178 ± 48.2	180 ± 39.8	166 ± 50.0	154 ± 30.3
	Pre-study (week 1)
	421 ± 110.1	335 ± 30.7	308 ± 92.2	314 ± 50.9	176 ± 48.0	174 ± 48.1	166 ± 48.0	142 ± 29.4
	Day 275b
	316 ± 92.9	284 ± 62.9	344 ± 89.3	459 ± 113.6*	172 ± 38.5	183 ± 30.2	251 ± 58.6	250 ± 58.0*

^aAll findings reversed by end of 4-week recovery period.

^bAll findings reversed by end of 13-week recovery period.

^*P ≤ 0.05, ^**P ≤ 0.01, ^***P ≤ 0.001.